No Prescription |
 |
 | ||
|
Prescription Drugs 6 |
|
| ||
No Prescription » Prescription Drugs 6
Diamicron MR Generic Gliclazide Diane 35 Generic Cyproterone acetate Diclocil Generic Dicloxacillin Differin Gel Generic Adapalene Dilantin Infatabs Generic Phenytoin Dilantin Paed Susp Generic Phenytoin Diprosone Cream Generic Betamethasone Dipropionate Diprosone Ointment Generic Betamethasone Dipropionate Diprosone OV Topical Cream Generic Betamethasone Dipropionate Diprosone OV Topical Ointment Generic Betamethasone Dipropionate Divina Generic Medroxyprogesterone DUPHASTON Generic Dydrogesterone Dynacirc SR Generic Isradipine Effexor XR Generic Venlafaxine Elidel Cream Generic Pimecrolimus Cream
No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
|
|
|